Joyce O’Shaughnessy, MD, provides insights on key studies in HR-positive/HER2-negative breast cancer from 2019 SABCS for Clinical Care Options (CCO)
Sara Tolaney, MD, MPH, provides insights on key studies on the treatment of HER2-negative and triple-negative breast cancer from 2019 SABCS for Clinical Care Options (CCO)
CME-certified Webcast of a CCO symposium at SABCS 2019 featuring expert perspectives on evolving strategies for treating HR-positive, HER2-negative advanced breast cancer
CCO faculty Dr. Heather McArthur provides insights on trastuzumab deruxtecan and tucatinib for patients with HER2+ MBC who have progressed on standard-of-care HER2-targeted therapies
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.